Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 8
2021 6
2022 9
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells.
Oh S, Mao X, Manfredo-Vieira S, Lee J, Patel D, Choi EJ, Alvarado A, Cottman-Thomas E, Maseda D, Tsao PY, Ellebrecht CT, Khella SL, Richman DP, O'Connor KC, Herzberg U, Binder GK, Milone MC, Basu S, Payne AS. Oh S, et al. Nat Biotechnol. 2023 Sep;41(9):1229-1238. doi: 10.1038/s41587-022-01637-z. Epub 2023 Jan 19. Nat Biotechnol. 2023. PMID: 36658341 Free PMC article.
Temporal Outcomes after Rituximab Therapy for Pemphigus Vulgaris.
Tovanabutra N, Bax CE, Feng R, Kushner CJ, Payne AS. Tovanabutra N, et al. J Invest Dermatol. 2022 Apr;142(4):1058-1064.e7. doi: 10.1016/j.jid.2021.09.013. Epub 2021 Oct 26. J Invest Dermatol. 2022. PMID: 34710389 Free PMC article.
Immune aging in multiple sclerosis is characterized by abnormal CD4 T cell activation and increased frequencies of cytotoxic CD4 T cells with advancing age.
Zuroff L, Rezk A, Shinoda K, Espinoza DA, Elyahu Y, Zhang B, Chen AA, Shinohara RT, Jacobs D, Alcalay RN, Tropea TF, Chen-Plotkin A, Monsonego A, Li R, Bar-Or A. Zuroff L, et al. EBioMedicine. 2022 Aug;82:104179. doi: 10.1016/j.ebiom.2022.104179. Epub 2022 Jul 19. EBioMedicine. 2022. PMID: 35868128 Free PMC article.
COVID-19 and MS disease-modifying therapies.
Berger JR, Brandstadter R, Bar-Or A. Berger JR, et al. Neurol Neuroimmunol Neuroinflamm. 2020 May 15;7(4):e761. doi: 10.1212/NXI.0000000000000761. Print 2020 Jul. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 32414755 Free PMC article.
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.
Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, Lenzi K, Rezk A, Patterson KR, Espinoza DA, Kadri JC, Markowitz DM, E Markowitz C, Mexhitaj I, Jacobs D, Babb A, Betts MR, Prak ETL, Weiskopf D, Grifoni A, Lundgreen KA, Gouma S, Sette A, Bates P, Hensley SE, Greenplate AR, Wherry EJ, Li R, Bar-Or A. Apostolidis SA, et al. Nat Med. 2021 Nov;27(11):1990-2001. doi: 10.1038/s41591-021-01507-2. Epub 2021 Sep 14. Nat Med. 2021. PMID: 34522051 Free PMC article.
AIRR Community Guide to Planning and Performing AIRR-Seq Experiments.
Eugster A, Bostick ML, Gupta N, Mariotti-Ferrandiz E, Kraus G, Meng W, Soto C, Trück J, Stervbo U, Luning Prak ET; AIRR Community. Eugster A, et al. Methods Mol Biol. 2022;2453:261-278. doi: 10.1007/978-1-0716-2115-8_15. Methods Mol Biol. 2022. PMID: 35622331 Free PMC article.
25 results